Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118975 · ClinicalTrials.gov registry record · Phase 1
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01118975 is a Phase 1 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 12 participants.
The verdict
NCT01118975, a Phase 1 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This research is being done to find out how safe and how well the combination of lapatinib and vorinostat works against advanced cancers.
Interventions
- DRUG Vorinostat
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01118975
The ClinicalTrials.gov registry entry for NCT01118975 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT01118975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01118975 about?
NCT01118975 is a clinical study titled "GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers". This research is being done to find out how safe and how well the combination of lapatinib and vorinostat works against advanced cancers.
What is the current status of trial NCT01118975?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-03. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01118975?
The interventions under investigation include: Vorinostat (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT01118975?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.